Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-52 is a potent inhibitor targeting the SARS-CoV-2 virus, exhibiting an inhibitory potency characterized by a pIC50 of 0.3187. This compound demonstrates significant antiviral activity and is suitable for research applications aimed at understanding and mitigating SARS-CoV-2 infections. Its mechanisms may provide valuable insights into therapeutic strategies against COVID-19. -
SARS-CoV-2 Nsp12 Inhibitor
Nsp12-IN-2 is a SARS-CoV-2 Nsp12 inhibitor, specifically targeting the RNA-dependent RNA polymerase (RdRp) activity of the Nsp12-Nsp7-Nsp8 complex. This compound terminates RNA synthesis and inhibits the RNAylation and NMPylation of Nsp9. Nsp12-IN-2 shows potential for research into SARS-CoV-2 infections, as well as studies involving other coronaviruses and RNA viruses. -
SARS-CoV Inhibitor
SARS-CoV-2 Mpro-IN-51 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 of 26 nM. This compound effectively targets the triple mutant variant L50F/E166A/L167F, making it a valuable tool for research into viral pathogenesis and therapeutic interventions. Its application extends to studies aimed at elucidating mechanisms of viral infection and drug resistance in SARS-CoV-2. -
SARS-CoV-2 3CL Protease Inhibitor
SARS-CoV-2 3CLpro-IN-33 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 1.5 nM. This compound demonstrates strong antiviral activity against SARS-CoV-2 in HEK293T-AT cells, with an EC50 of 0.017 μM. SARS-CoV-2 3CLpro-IN-33 is suitable for research applications focused on understanding COVID-19 infection and developing therapeutic strategies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 PLpro-IN-1 is a non-covalent, competitive inhibitor specifically targeting the SARS-CoV-2 PLpro enzyme. It demonstrates significant biological activity with an IC50 of 15.06 μM and a Ki value of 22.93 μM. Furthermore, SARS-CoV-2 PLpro-IN-1 effectively inhibits the proliferation of Vero cells, exhibiting an IC50 of 7.47 μM. This compound is suitable for research applications focused on viral inhibition and understanding the mechanisms of SARS-CoV-2 replication. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-67 is a vitamin K derivative that serves as an inhibitor of SARS-CoV-2. It exhibits significant antiviral activity against SARS-CoV-2, with an EC50 of 64.8 μM in VeroE6/TMPRSS2 cells. This compound specifically targets and inhibits the activity of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), making it a valuable reagent for research applications in virology and the study of coronavirus infections. -
SARS-CoV-2 Inhibitor
Jobosic acid is a saturated fatty acid that functions as a selective inhibitor of SARS-CoV-2. It effectively inhibits the main protease (Mpro) and the spike receptor binding domain (RBD) interaction with ACE-2, demonstrating IC50 values of 7.5 μg/mL and 3 μg/mL, respectively. Jobosic acid also exhibits inhibitory effects on viral entry for the omicron variant of SARS-CoV-2, making it a valuable compound for research in antiviral therapies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-69 is a non-covalent inhibitor specifically targeting the SARS-CoV-2 main protease (Mpro) with an EC50 value of 7.4 μM. This compound demonstrates potent inhibitory activity against Mpro and also acts as a non-covalent inhibitor of papain-like protease (PLpro). It is suitable for studies aimed at understanding the mechanisms of SARS-CoV-2 replication and for the development of antiviral therapeutics. -
SARS-CoV-2 Mac1-ADP-ribose Inhibitor
F594-1001 is a selective inhibitor of the SARS-CoV-2 Mac1-ADP-ribose activity, demonstrating IC50 values of 8.5 μM, 68 μM, and 45 μM in AS, FP, and FRET assays, respectively. This compound directly interacts with the Mac1 enzyme, resulting in dose-dependent inhibition of ADP-ribosylhydrolase activity. F594-1001 is valuable for research focused on understanding SARS-CoV-2 biology and developing therapeutic strategies against COVID-19. -
SARS-CoV-2-specific Entry Inhibitor
SARS-CoV-2-IN-120 is a specific entry inhibitor targeting the SARS-CoV-2 spike protein. By binding to and trimerizing within the apex cavity of the spike trimer, it effectively blocks the interaction between the receptor-binding domain (RBD) and ACE2. This compound demonstrates potent neutralization against the BA.2 lineage and subsequent Omicron variants, and has shown capabilities in inhibiting SARS-CoV-2 replication in murine models. SARS-CoV-2-IN-120 is valuable for research applications focused on viral entry mechanisms and therapeutic development against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-46 is an inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of approximately 25 μM. This compound demonstrates significant antiviral activity with low cytotoxicity, as indicated by an IC50 value of 7.4 μM against SARS-CoV-2. SARS-CoV-2 Mpro-IN-46 is suitable for research applications focused on understanding and combating coronavirus infections, particularly in the context of COVID-19. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-21 is an irreversible and covalent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 of 0.03 µM. Additionally, it demonstrates activity against the SARS-CoV-1 3CLpro with an IC50 of 0.12 µM. This compound is valuable for investigative research into viral protease inhibition and potential therapeutic strategies against SARS-CoV-2 infections. -
SARS-CoV-2 Papain-like Protease Inhibitor
SARS-CoV-2-IN-106 is a potent inhibitor of the SARS-CoV-2 papain-like protease (PLpro), demonstrating IC50 values of 0.44 μM for enzymatic activity and 0.18 μM for viral replication. This compound is crucial for research into SARS-CoV-2 infection mechanisms and for the development of antiviral therapies targeting protease enzymes. Its efficacy makes it a valuable tool for studying coronavirus biology and potential treatments. -
SARS-CoV-2 PLpro/Mpro Inhibitor
SARS-CoV-2-IN-68 is a covalent inhibitor targeting the SARS-CoV-2 PLpro and Mpro proteases. This compound exhibits significant antiviral activity by binding to the Zn-finger domain of PLpro, thereby disrupting viral replication. It serves as a valuable tool in research focused on developing therapeutic strategies against SARS-CoV-2 infections. -
SARS-CoV-2 PLpro Inhibitor
9-Aminominocycline is a potent inhibitor of the SARS-CoV-2 papain-like protease (PLpro), effectively disrupting its deubiquitination and protease activities with IC50 values of 4.55 µM and 4.15 µM, respectively. This compound demonstrates antiviral activity against SARS-CoV variants, including Delta and Omicron, with IC50 values of 1.04 µM and 2.35 µM in Calu-3 cells. It is a valuable research tool for investigating therapeutic strategies against SARS-CoV-2 and related coronaviruses. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-92 is a potent inhibitor specifically targeting SARS-CoV-2 variants, with an EC50 value of 0.48 μM. This compound also exhibits inhibitory activity against SARS-CoV and MERS-CoV, demonstrating its broad-spectrum antiviral potential. SARS-CoV-2-IN-92 selectively blocks the interaction with the estrogen receptor alpha (ERα-Glu II), highlighting its relevance in research applications focused on viral inhibition and receptor modulation. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-52 is a potent inhibitor of the SARS-CoV-2 main protease (MPro), demonstrating an EC50 of 0.0099 µM. It exhibits broad-spectrum antiviral activity against other coronaviruses, including MERS, OC43, and 229E, with EC50 values of 0.00961 µM, 0.138 µM, and 0.117 µM, respectively. This compound is suitable for research applications focusing on the development of antiviral therapeutics for COVID-19 and related viral infections. -
TMV Inhibitor
TMV-IN-12 is a potent inhibitor of tobacco mosaic virus (TMV), targeting the aggregation and self-assembly of TMV capsid protein (TMV-CP) with a dissociation constant (Kd) of 0.142 μM. This compound effectively disrupts TMV particle formation, thereby preventing the infection of tobacco plants. Additionally, TMV-IN-12 exhibits antifungal properties, making it a valuable reagent for studying viral and fungal interactions in plant biology and for developing strategies to combat TMV-related diseases. -
Virus Protease Inhibitor
AG-7404 is an orally active, irreversible inhibitor of the picornavirus 3C protease, which disrupts the processing of viral polyproteins and effectively inhibits viral replication. This compound demonstrates synergistic antiviral activity when used alongside capsid inhibitors, making it valuable for research on enterovirus infections, including poliovirus. AG-7404 is particularly useful in studies involving V-073-resistant viral variants, contributing to a deeper understanding of antiviral mechanisms and potential therapies. -
Flaviviruse Inhibitor
Flaviviruses-IN-3 is a potent inhibitor specifically targeting flaviviruses. This compound demonstrates significant activity by reducing West Nile virus (WNV) protease activity, achieving an impressive inhibition rate of 54%. Flaviviruses-IN-3 is applicable for research into therapeutic strategies against flavivirus-related diseases and contributes to the understanding of viral protease functions. -
NS2B/NS3 Inhibitor
NS2B/NS3-IN-5 is an allosteric inhibitor targeting the NS2B/NS3 protease of Dengue Virus Serotype 2 (DENV2) and Zika Virus (ZIKV). It demonstrates effective inhibitory activity with IC50 values of 0.67 µM against ZIKV and 4.38 µM against DENV2 NS2B/NS3 proteases. This compound presents significant potential for research applications in virology, specifically in the development of antiviral therapies targeting these flavivirus proteases. -
MTase Inhibitor
NSC 288387 is a pan-flavivirus methyltransferase (MTase) inhibitor that targets the S-adenosylmethionine (SAM) binding pocket. It demonstrates significant antiviral activity, inhibiting Zika virus (ZIKV) replication with an IC50 of 0.2 μM. This compound is useful in research applications focused on flavivirus infections and the mechanisms of viral replication. -
Flaviviruses Inhibitor
Flaviviruses-IN-2 is a potent inhibitor targeting flavivirus proteases, particularly effective against the West Nile virus (WNV). This compound significantly reduces WNV protease activity, achieving an inhibition level of 56%. Flaviviruses-IN-2 is primarily utilized in research applications focused on understanding flaviviral pathogenesis and developing antiviral therapeutics. -
NS2B/NS3 Inhibitor
NS2B/NS3-IN-4 is an allosteric inhibitor targeting the NS2B/NS3 protease of dengue virus serotype 2 (DENV2) and Zika virus (ZIKV). It demonstrates IC50 values of 0.69 µM for DENV2 and 1.04 µM for ZIKV proteases, highlighting its potent enzymatic inhibition. This compound serves as a valuable tool in antiviral research, particularly for elucidating mechanisms of viral replication and developing therapeutic strategies against flavivirus infections. -
NS2B/NS3 Inhibitor
NS2B/NS3-IN-6 is an allosteric inhibitor targeting the NS2B/NS3 protease of Dengue virus (DENV) and Zika virus (ZIKV). It exhibits IC50 values of 2.23 µM and 25.2 µM against ZIKV and DENV proteases, respectively. This compound is valuable for research applications focused on developing antiviral therapies and understanding the enzymatic mechanisms of flavivirus proteases. -
HIV-1 Protease Inhibitor
(Rac)-PD 135390 is a potent HIV-1 protease inhibitor, exhibiting an IC50 of 2 nM. This dipeptide is instrumental in antiviral research, providing insights into HIV-1 protease activity and potential therapeutic interventions. Its efficacy in inhibiting viral replication makes it a valuable tool for studying HIV pathogenesis and drug resistance. -
DENV2 Inhibitor
YKL-04-085 is a potent inhibitor of dengue virus serotype 2 (DENV2) translation, demonstrating an IC90 of 0.555 μM. This compound specifically targets viral translation mechanisms, making it a valuable tool for research on DENV2 pathogenesis and antiviral drug development. Additionally, YKL-04-085 shows no kinase activity, allowing for more targeted investigations into its antiviral efficacy. -
PRRSV Inhibitor
PRRSV-IN-1 is a non-structural protein 4 (nsp4) protease inhibitor specifically targeting Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). This compound demonstrates potent antiviral activity, exhibiting an EC50 of 0.45 μM and effectively inhibiting nsp4 protease activity with an IC50 of 80.36 pM. PRRSV-IN-1 is a valuable tool for investigating antiviral strategies and understanding PRRSV pathogenesis in research applications. -
HBV Inhibitor
Coclauril is a potent inhibitor of Hepatitis B virus (HBV) replication, acting primarily on hepatocytes. It demonstrates antiviral activity in human hepatoblastoma cell lines, with an EC50 value of 7.6 μg/mL. Coclauril is utilized in research to explore therapeutic strategies against HBV and to study the mechanisms of viral replication inhibition. -
HBV Inhibitor
BAY39-5493 is a non-nucleoside inhibitor targeting hepatitis B virus (HBV) replication. It exerts its biological activity by blocking the formation of viral core particles, thereby inhibiting viral DNA replication. With an IC50 value of 0.03 μM against HBV in stably transfected HepG2.2.15 cells, BAY39-5493 serves as a valuable tool for research in the field of antiviral therapeutics and HBV biology. -
HBV Inhibitor
BAY38-7690 is a non-nucleoside inhibitor that specifically targets hepatitis B virus (HBV) replication. It functions by obstructing the assembly of viral core particles, thereby inhibiting viral DNA replication. With an IC50 value of 0.15 μM in stably transfected HepG2.2.15 cells, BAY38-7690 is an important tool for investigating HBV biology and evaluating potential therapeutic strategies against hepatitis B virus infections. -
HBV Inhibitor
Personalised postprandial-targeting is an HBV inhibitor that modulates water-heme interactions, specifically targeting low-spin cytochrome P450 complexes. This reagent effectively preserves the axial water ligands of CYP2C9, even when inhibitors are present, enabling advanced studies of enzyme dynamics. Additionally, it facilitates the observation of hydrogen atoms in the axial water ligands through EPR spectroscopy, offering valuable insights into the active site of the enzyme, making it a critical tool for research in enzymology and drug development. -
HBV Inhibitor
GS-8873 TFA is a potent inhibitor of hepatitis B virus (HBV) surface antigen (HBsAg) production, exhibiting an EC50 value of 4 nM. This orally bioavailable compound demonstrates favorable pharmacokinetic properties in rodent models and metabolic stability in human hepatocytes. Notably, GS-8873 TFA has been associated with neurofunctional deficits in both rats and cynomolgus monkeys, making it a valuable tool for research in HBV therapies and associated neurological effects. -
Nucleotide Reverse Transcriptase Inhibitor
Tenofovir disoproxil aspartate is a nucleotide reverse transcriptase inhibitor primarily targeting HIV and chronic Hepatitis B. It demonstrates potent antiviral activity by interfering with viral RNA replication, ultimately leading to reduced viral load in infected patients. This compound is essential in research aimed at developing effective therapeutic strategies against retroviral infections. -
HCV/SARS-CoV-2 Inhibitor
Bemnifosbuvir is a potent inhibitor of Hepatitis C virus (HCV) replication with demonstrated efficacy against SARS-CoV-2. This orally active compound exhibits significant antiviral activity in vitro, achieving an effective concentration (EC90) of 0.47 μM against COVID-19. Bemnifosbuvir displays pangenotypic activity, making it a valuable tool for research into antiviral therapies for both HCV and SARS-CoV-2 infections. -
HCV/SARS-CoV-2 Inhibitor
Bemnifosbuvir hemisulfate is a potent inhibitor of HCV viral replication and a promising antiviral agent against SARS-CoV-2. This guanosine nucleotide proagent exhibits significant efficacy in vitro, demonstrating an EC90 value of 0.47 μM against COVID-19. Bemnifosbuvir hemisulfate also shows pangenotypic antiviral activity, making it a valuable tool for research in viral infections and therapeutic development. -
HCV/HIV Inhibitor
C5A is a microbicidal peptide that targets and inhibits both hepatitis C virus (HCV) and human immunodeficiency virus (HIV). By disrupting the membrane integrity of the HIV virion and affecting the conical capsid core that encases the viral genome, C5A significantly reduces the infectivity of a wide range of HIV isolates in various primary target cells in vitro. Additionally, studies have demonstrated that C5A offers protective effects in mice against vaginal and rectal challenges with HIV, highlighting its potential utility in antiviral research applications. -
COVID-19 Inhibitor
RBT-9 is a COVID-19 inhibitor that targets viral replication and inflammation pathways. It has demonstrated efficacy in preventing the progression to severe COVID-19 and associated organ failure. Furthermore, RBT-9 exhibits antiviral activity against various enveloped viruses, including influenza, hepatitis C virus (HCV), dengue, and yellow fever, making it a valuable tool for research in viral pathogenesis and therapeutic intervention. -
Serine β-Lactamase Inhibitor
Pilabactam is a potent covalent inhibitor of serine β-lactamases, exhibiting IC50 values between 1 nM and 175 nM across various serine β-lactamase types. This compound significantly enhances the efficacy of β-lactam antibiotics against challenging pathogens such as Carbapenem-Resistant Enterobacterales (CRE) and Acinetobacter baumannii (CRAB). Pilabactam is valuable in research focused on bacterial infections and antibiotic resistance mechanisms. -
Bacterial Inhibitor
Pyrroxamycin is a novel antibiotic with a primary mechanism targeting Gram-positive bacteria and dermatophytes. Derived from the fermentation of Streptomyces, it exhibits potent antibacterial activity. This compound has potential applications in pharmaceutical research for the development of new antimicrobials, particularly against resistant bacterial strains. Detailed analysis of its chemical structure was performed using X-ray crystallography and 13C NMR spectroscopy, elucidating its physicochemical properties and enhancing its utility in microbiological studies. -
Quorum Sensing Inhibitor
Aculene D is a quorum sensing inhibitor derived from fungal metabolites that targets the signaling mechanisms in bacteria. It effectively reduces violacein production in Chromobacterium violaceum CV026 cultures induced by N-hexanoyl-L-homoserine lactone (C6-HSL) at sub-inhibitory concentrations. This compound is valuable for research exploring bacterial communication and the modulation of biofilm formation, with potential applications in combating antibiotic resistance and developing new antimicrobial strategies. -
β-lactamase Inhibitor
β-Lactamase-IN-5 is a potent β-lactamase inhibitor that serves to enhance the efficacy of β-lactam antibiotics against resistant bacterial strains. Its primary mechanism involves the inhibition of β-lactamase enzymes, which are responsible for antibiotic resistance. This compound is valuable for research applications aimed at understanding and combating bacterial infections, particularly those caused by multidrug-resistant pathogens. -
Bacterial Inhibitor
β-Lactamase-IN-6 is a potent inhibitor of β-Lactamase enzymes, which play a crucial role in bacterial resistance to β-lactam antibiotics. This compound demonstrates significant antibacterial activity by preventing the enzymatic breakdown of β-lactam antibiotics, thereby enhancing their effectiveness against resistant bacterial strains. β-Lactamase-IN-6 serves as a valuable tool in microbiological research and antibiotic development, providing insights into combating bacterial infections and resistance mechanisms. -
Bacterial Inhibitor
(R)-Gyramide A hydrochloride is a bacterial DNA gyrase inhibitor that effectively disrupts DNA supercoiling, exhibiting an IC50 of 3.3 µM. This compound demonstrates significant antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Salmonella enterica, with minimum inhibitory concentrations ranging from 10 to 80 µM. Notably, (R)-Gyramide A hydrochloride does not inhibit topoisomerase IV, making it a valuable tool for studying bacterial mechanisms and antibiotic resistance. -
Bacterial Inhibitor
Acrisorcin is a topical anti-infective compound that functions primarily as a bacterial inhibitor. It exhibits potent fungicidal properties, making it valuable for research into antifungal therapies and the understanding of bacterial resistance mechanisms. Its efficacy in mitigating fungal infections supports its application in various microbiological studies and therapeutic evaluations. -
Bacterial Inhibitor
CID21480113 is an inhibitor targeting bacterial pathways, specifically effective against dapsone-resistant strains of leprosy. This compound demonstrates significant antibacterial activity, making it a valuable tool for research in microbial resistance and infectious disease studies. Its ability to combat resistant bacteria positions CID21480113 as a relevant reagent for investigations into alternative therapies for leprosy. -
Bacterial Inhibitor
o-Cymen-5-ol acts as a broad-spectrum antimicrobial agent targeting various bacterial and fungal pathogens. It demonstrates effective minimum inhibitory concentrations (MICs) against organisms such as Streptococcus mutans and Candida albicans. Notably, o-Cymen-5-ol exhibits synergistic effects when combined with zinc, enhancing its antimicrobial activity against oral pathogens by inhibiting glycolysis. Studies indicate a more pronounced antibacterial effect in formulations such as toothpaste compared to placebo. This compound is valuable for research applications in microbiology and dental health. -
Bacterial Inhibitor
Strinoline is a bacterial inhibitor that targets and disrupts bacterial cell function. This compound exhibits significant antibacterial activity, making it a valuable tool for research in the field of microbiology. Strinoline can be utilized to study bacterial resistance mechanisms and the efficacy of antibiotic therapies. -
Bacterial IMPDH Inhibitor
IMPDH-IN-1 is a selective inhibitor of bacterial inosine 5'-monophosphate dehydrogenase (IMPDH), targeting the catalytic domain of the enzyme. This compound demonstrates potent inhibitory activity against IMPDH from key bacterial pathogens, including Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli. It serves as a valuable tool for research into bacterial metabolism and the development of novel antimicrobial therapies. -
Bacterial Inhibitor
4-Hydroxysphinganine (C17 base) is a bacterial inhibitor that plays a critical role in membrane structure for various organisms, including fungi, plants, and bacteria. It is essential for maintaining membrane integrity, regulating cellular growth, and facilitating the heat stress response in yeast. Additionally, 4-Hydroxysphinganine acts as a precursor for the synthesis of key lipid mediators, such as PHS 1-phosphate and inositol phosphorylceramide. Its properties also support keratinocyte differentiation, making it relevant for applications in dermatology and cosmetic research.
